MapLight Therapeutics, Inc. Common Stock (MPLT)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 133
- Market Cap
- $636M
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
SentiSense also tracks daily options readings for MapLight Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
MapLight Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.